Fort Lauderdale-based Aim Medical Robotics raised millions to support the development of its robotic-assisted platform for neurosurgery.
The company secured $3.4 million in seed funding in a financing round led by Surrey Capital Partners and IQ Capital, a venture capital firm headquartered in the United Kingdom. Aim will use the funding to accelerate the development of a portable MRI-compatible surgical robot designed to improve outcomes for patients undergoing surgery for functional brain disorders and cancer.
"Aim is on an exciting journey to develop and commercialize an industry-first in robot-assisted surgery," said founder and CEO Bob Cathcart.
Before starting Aim in 2018, Cathcart served as CEO of Baltimore-based Clear Guide Medical, an image-guided surgical company; and senior VP of global sales for medical device firm Hansen Medical in Mountain View, California.
On top of improving patient outcomes, Aim reports its robotic-assisted platform provides cost savings to hospitals by eliminating surgical errors and reducing procedure times by up to 50%.
IQ Capital Managing Partner Ed Stacey said Aim's technology has the potential to "transform surgery" as we know it.
"Aim's MRI-compatible robotics platform opens the door to unprecedented levels of surgical precision and novel categories of surgical procedures," he said.
For more stories like this one, sign up for Miami Inno newsletters from the South Florida Business Journal and the American Inno network.
